ReviewPLoS neglected tropical diseases2019
Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host.
Review in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- Genomic instability and mono-parental expression mitigate genomic shock in a cross-subgenusNAR molecular medicine · 2026Article
- Trypanothione reductase overexpression increases the infectivity ofFrontiers in cellular and infection microbiology · 2026Article
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- UnveilingInternational journal for parasitology. Parasites and wildlife · 2025Article
- Leishmania (Leishmania) infantum and Leishmania (Sauroleishmania) tarentolae in outdoor cats and report of infection in feline-derived peripheral blood mononuclear cells.Parasites & vectors · 2025Article
- Molecular detection ofInternational journal for parasitology. Parasites and wildlife · 2025Article
- Evaluation of various membranes for blood-feeding in nine sand fly species and artificial feeding challenges in Sergentomyia minuta.Parasites & vectors · 2025Article
- Recombinant protein expression inFrontiers in bioengineering and biotechnology · 2025Article
- hsp70 PCR-RFLP as an alternative tool to identify Sauroleishmania species.Parasitology research · 2024Article
- Leishmania spp. in equids and their potential vectors in endemic areas of canine leishmaniasis.PLoS neglected tropical diseases · 2024Article
- A novel chemically defined medium for the biotechnological and biomedical exploitation of the cell factory Leishmania tarentolae.Scientific reports · 2024Article
- Immunomodulatory properties ofFrontiers in parasitology · 2024Article
- The non-pathogenic protozoonFrontiers in immunology · 2024Article
- A Modular Cloning Toolkit for the production of recombinant proteins inMicrobial cell (Graz, Austria) · 2024Article
- Is leishmaniasis the new emerging zoonosis in the world?Veterinary research communications · 2023Review
- Evolution of RNA viruses in trypanosomatids: new insights from the analysis of Sauroleishmania.Parasitology research · 2023Article
- Experimental feeding of Sergentomyia minuta on reptiles and mammals: comparison with Phlebotomus papatasi.Parasites & vectors · 2023Article
- Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral infections.Parasites & vectors · 2023Review
- Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.The Korean journal of parasitology · 2022Article
- Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19.Pharmacological research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we summarize the current knowledge concerning the eukaryotic protozoan parasite Leishmania tarentolae, with a main focus on its potential for biotechnological applications. We will also discuss the genus, subgenus, and species-level classification of this parasite, its life cycle and geographical distribution, and similarities and differences to human-pathogenic species, as these aspects are relevant for the evaluation of biosafety aspects of L. tarentolae as host for recombinant DNA/protein applications. Studies indicate that strain LEM-125 but not strain TARII/UC of L. tarentolae might also be capable of infecting mammals, at least transiently. This could raise the question of whether the current biosafety level of this strain should be reevaluated. In addition, we will summarize the current state of biotechnological research involving L. tarentolae and explain why this eukaryotic parasite is an advantageous and promising human recombinant protein expression host. This summary includes overall biotechnological applications, insights into its protein expression machinery (especially on glycoprotein and antibody fragment expression), available expression vectors, cell culture conditions, and its potential as an immunotherapy agent for human leishmaniasis treatment. Furthermore, we will highlight useful online tools and, finally, discuss possible future applications such as the humanization of the glycosylation profile of L. tarentolae or the expression of mammalian recombinant proteins in amastigote-like cells of this species or in amastigotes of avirulent human-pathogenic Leishmania species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.